Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01916863 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01916863 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT01916863, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo.
Interventions
- DRUG LX4211 Placebo
- DRUG LX4211 400 mg
- DRUG canagliflozin 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01916863
The ClinicalTrials.gov registry entry for NCT01916863 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LX4211 Placebo is the first listed.
NCT01916863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01916863 about?
NCT01916863 is a clinical study titled "Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects". The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo.
What is the current status of trial NCT01916863?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2013-08.
What interventions are being tested in trial NCT01916863?
The interventions under investigation include: LX4211 Placebo (DRUG), LX4211 400 mg (DRUG), canagliflozin 300 mg (DRUG).
Who is sponsoring clinical trial NCT01916863?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.